+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

IgA Nephropathy Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments

  • ID: 4542607
  • Report
  • May 2018
  • Region: Global
  • 97 Pages
  • Knowledge Sourcing Intelligence LLP

FEATURED COMPANIES

  • Alexion Pharmaceuticals
  • ChemoCentryx, Inc.
  • IGAN Biosciences, Inc.
  • Merck KGaA
  • Omeros Corporation
  • Retrophin, Inc
IgA Nephropathy Pipeline Analysis report covers 17 drugs currently in different phases of development. IgA Nephropathy is also known as Berger’s disease occurs when there is an accumulation of immunoglobulin A (IgA) in the kidneys. This gives rise to kidney inflammation and may damage the kidney’s ability to filter waste, slowly with time. The disease is asymptomatic in the beginning and can be detected only by routine tests. Presence of protein and red blood cells in the urine of a person suffering from IgA Nephropathy can be seen through a microscope.

The report provides IgA Nephropathy treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.

Major industry players profiled as part of the report are Merck KGaA, Pfizer Inc., Rigel Pharmaceuticals, Inc. and Apellis Pharmaceuticals among others.

Scope:
  • By Company

  • By Phase

  • By Molecule Type

  • By Region

  • By Route of Administration

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Alexion Pharmaceuticals
  • ChemoCentryx, Inc.
  • IGAN Biosciences, Inc.
  • Merck KGaA
  • Omeros Corporation
  • Retrophin, Inc

1. Introduction
1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region
2. Disease Overview
2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology
3. Executive Summary
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities
5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profiling
  • Drug Name

  • Generic Name

  • Synonyms

  • Company

  • Collaborator

  • Route of administration

  • Target

  • Mechanism of Action

  • Technology

  • Molecule type

  • CAS Number

  • Weight

  • Chemical Formula

  • IUPAC name

  • ATC code


5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region
6. Company profiling
6.1. Merck KGaA
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.2. Rigel Pharmaceuticals Inc.
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.3. Calliditas Therapeutics AB
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
6.4. Anthera Pharmaceuticals, Inc.
6.4.1. Introduction
6.4.2. Financials
6.4.3. Products and Services
6.4.4. SWOT
6.5. ChemoCentryx, Inc.
6.5.1. Introduction
6.5.2. Financials
6.5.3. Products and Services
6.5.4. SWOT
6.6. Pfizer Inc.
6.6.1. Introduction
6.6.2. Financials
6.6.3. Products and Services
6.6.4. SWOT
6.7. Apellis Pharmaceuticals
6.7.1. Introduction
6.7.2. Financials
6.7.3. Products and Services
6.7.4. SWOT
6.8. Reata Pharmaceuticals, Inc.
6.8.1. Introduction
6.8.2. Financials
6.8.3. Products and Services
6.8.4. SWOT
6.9. Omeros Corporation
6.9.1. Introduction
6.9.2. Financials
6.9.3. Products and Services
6.9.4. SWOT
6.10. Visterra, Inc.
6.10.1. Introduction
6.10.2. Financials
6.10.3. Products and Services
6.10.4. SWOT
6.11. Novartis AG
6.11.1. Introduction
6.11.2. Financials
6.11.3. Products and Services
6.11.4. SWOT
6.12. Mallinckrodt
6.12.1. Introduction
6.12.2. Financials
6.12.3. Products and Services
6.12.4. SWOT
6.13. Shire
6.13.1. Introduction
6.13.2. Financials
6.13.3. Products and Services
6.13.4. SWOT
6.14. IGAN Biosciences, Inc.
6.14.1. Introduction
6.14.2. Financials
6.14.3. Products and Services
6.14.4. SWOT
6.15. Alexion Pharmaceuticals
6.15.1. Introduction
6.15.2. Financials
6.15.3. Products and Services
6.15.4. SWOT
6.16. Retrophin, Inc
6.16.1. Introduction
6.16.2. Financials
6.16.3. Products and Services
6.16.4. SWOT
6.17. Genosco
6.17.1. Introduction
6.17.2. Financials
6.17.3. Products and Services
6.17.4. SWOT
List of Tables
List of Figures
Note: Product cover images may vary from those shown
  • Merck KGaA

  • Rigel Pharmaceuticals Inc.

  • Calliditas Therapeutics AB

  • Anthera Pharmaceuticals, Inc.

  • ChemoCentryx, Inc.

  • Pfizer Inc.

  • Apellis Pharmaceuticals

  • Reata Pharmaceuticals, Inc.

  • Omeros Corporation

  • Visterra, Inc.

  • Novartis AG

  • Mallinckrodt

  • Shire

  • IGAN Biosciences, Inc.

  • Alexion Pharmaceuticals

  • Retrophin, Inc

  • Genosco

Note: Product cover images may vary from those shown

RELATED TAGS

RELATED PRODUCTS

IgA Nephropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - Product Image

IgA Nephropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

  • Report
  • 73 Pages
  • Region: Global
Diabetic Nephropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Image

Diabetic Nephropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • 207 Pages
  • Region: Global
Diabetic Nephropathy Global Market Insights 2021, Analysis and Forecast to 2026, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Diabetic Nephropathy Global Market Insights 2021, Analysis and Forecast to 2026, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 115 Pages
  • Region: Global
Contrast Induced Nephropathy Pipeline Drugs and Companies, 2021- Phase, Mechanism of Action, Route, Licensing/Collaboration, Pre-clinical and Clinical Trials - Product Image

Contrast Induced Nephropathy Pipeline Drugs and Companies, 2021- Phase, Mechanism of Action, Route, Licensing/Collaboration, Pre-clinical and Clinical Trials

  • Report
  • 70 Pages
  • Region: Global
Diabetic Nephropathy - Epidemiology Forecast to 2032 - Product Image

Diabetic Nephropathy - Epidemiology Forecast to 2032

  • Report
  • 60 Pages
  • Region: Global
Copyright © 2002-2022 Research and Markets. All Rights Reserved.